Embodiments relate generally to medical devices and, more particularly, to housing arrangements for infusion pumps in the form of syringe pumps and large volume pumps (LVPs).
In the medical arts, infusion pumps have been useful for managing the delivery and dispensation of a prescribed amount or dose of a drug, fluid, fluid-like substance, or medicament (hereinafter, collectively, an “infusate”) to patients. Infusion pumps can provide some significant advantages over manual infusion techniques, by accurately delivering and dispensing infusates over an extended period of time.
Infusion pumps are particularly useful for treating diseases and disorders that require regular pharmacological intervention, including cancer, diabetes, and vascular, neurological, and metabolic disorders. They also enhance the ability of healthcare providers to deliver anesthesia and manage pain. Infusion pumps are used in various settings, including hospitals, nursing homes, and other short-term and long-term medical facilities, as well as in residential care settings. Infusion pumps can include various constructions, modes of operation, and types.
Generally, infusion pumps can include a variety of types of pumps. In some cases, these infusion pumps include syringe pumps and LVPs. Depending upon their specific designs and intended uses, infusion pumps can be used to administer infusates through various delivery methods and routes, including intravenously, intraperitoneally, enterally, intra-arterially, subcutaneously, neuraxially, and specifically into an intraoperative site, epidural space, and subarachnoid space.
While various syringe pumps and LVPs have been used in medical environments for many years, these devices remain rather complex medical devices with some limitations to their efficient, effective, and safe use. Therefore, there is a need for syringe pumps and LVPs which provide greater flexibility and ease of use to operators. Moreover, due to the vital role of infusion pumps in many medical procedures and treatments, syringe pumps and LVPs which provide enhanced safety to patients are needed as well.
Embodiments described or otherwise contemplated herein substantially provide the advantages of improving flexibility, ease of use, operation, as well as patient safety, among other advantages.
An embodiment relates to an infusion pump, including a housing, a user interface, a motor and a set of drive components, and a controller. The housing enables selective stacked attachment with other infusion pumps. The housing includes a top portion with a handle integrated into an outer surface that partially defines a generally U-shaped retaining feature. The housing also includes a bottom portion with a generally U-shaped projection contoured to selectively mate with a retaining feature of another infusion pump. The user interface provides a front side to the housing that receives commands regarding infusion pump operation. The motor and set of drive components are at least partially located within the housing and mechanically direct infusion of an infusate. The controller is located within the housing and controls operation of the motor and the set of drive components.
An embodiment relates to a syringe pump, including a syringe receptacle, a syringe plunger driver assembly, and a housing. The syringe receptacle is configured to receive a syringe of an infusate. The syringe plunger driver assembly is located adjacent the syringe receptacle and directs the infusate from the syringe to a patient based on movement and force against a plunger of the syringe. The housing is coupled with the syringe receptacle and has a front side that includes a graphical user interface (GUI) display for controlling the syringe pump. The syringe receptacle is located on the front side of the housing vertically adjacent the GUI display in non-overlapping and non-visually obscuring alignment. The housing is configured such that both the syringe in the syringe receptacle and the entire GUI display are substantially visible on the front side of the housing.
An embodiment includes an infusion pump assembly. The infusion pump assembly includes a first infusion pump having a housing and a user interface with a display screen. The infusion pump assembly also has a “headless” infusion pump having no display screen. The headless infusion pump is releasably coupled to the housing of the first infusion pump by tongue-and-groove attachment.
An embodiment relates to a “field replaceable unit” for infusion pumps. The field replaceable unit includes a rear housing for an infusion pump. The rear housing includes a top portion and a bottom portion. The top portion has an integrally formed handle structure and a set of grooves. The bottom portion has a projection for releasable coupling with grooves in another rear housing. The rear housing includes a power receptacle and an Ethernet port. The rear housing interchangeably couples with a set of medication delivery components, a control system, and a display of either a LVP or a syringe pump.
The above summary is not intended to describe each illustrated embodiment or every implementation of the subject matter hereof. The figures and the detailed description that follow more particularly exemplify various embodiments.
Subject matter hereof may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying figures, in which:
While various embodiments are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the claimed subject matter to particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter as defined by the claims.
In
“LVPs” can take on various forms, but are typically infusion pumps coupled to one or more reservoirs configured to hold or store a relatively large amount of infusate or infusates, such as a cassette, IV bag, or other self-contained source. As used throughout this disclosure, the term “LVP” is intended to generally pertain to any medical infusion pump or device capable of large volume infusion to a patient.
Syringe Pump
Referring first to
As seen in
In some embodiments, certain commands or instructions are not controlled by a touchscreen, such as a display screen 118 and, instead, are controlled by a keypad 120. Keypad 120 is located adjacent to the display screen 118 and presents a variety of buttons and indicator lights. In some embodiments, push buttons requiring physical mechanical actuation are used on the keypad 120 for certain user commands, including: on/off power; audible alarm mute; start infusion, and stop infusion. Additional or fewer buttons on keypad 120 are contemplated as well. Physical mechanical actuation buttons, for primary or redundant purposes, provide increased safety and reliability to operators in cases where the touchscreen of a display 118 does not function properly, or is otherwise difficult to manipulate correctly. Having a user interface 110 including both a display screen 118 and a keypad 120, accordingly, provides the flexibility of a screen interface as well as the enhanced safety and reliability of physical control buttons.
The housing 112 generally forms a protective shell surrounding the internal components of the syringe pump 100. In some embodiments, the user interface 110 may be considered part of the housing 112. The housing 112 can be characterized as generally comprising a front housing assembly 122 and a rear housing assembly 124. Front housing assembly 122 generally surrounds the LCD display screen 118, keypad 120 and other components around the user interface 110. The front housing assembly 122 includes side panels 126 along the front portion of the syringe pump 100. A grouping of small holes can be located on one or both side panels 126 of the front housing 122 for audio speakers 128.
As illustrated in, for example,
As illustrated in, for example,
In addition to the upper lip portion 138, the generally U-shaped retaining feature 136 further includes a set of receiving grooves 140 (as partially illustrated in, for example,
As illustrated in, for example,
As shown in
The forward portion 156 of the generally U-shaped projection 152 is located in the middle of the “U” shape. The forward portion 156 forms a tightly curved “U” shape. The forward portion 156 provides a surface that can abut up against and mate with a corresponding surface of a pump or device, similar to that of narrowed section 144 of the generally U-shaped retaining feature 136 on the top portion 130 of the housing 112. The rearward portions 158 of the generally U-shaped projection 152 each provide segments of wider separation than the sides of the forward portion 156. The rearward portions 158 of the generally U-shaped projection 152 include a flange 160 with an outwardly extending lip 162 as illustrated in, for example,
In
With reference again to, for example,
Male and female connector portions can be keyed or otherwise restricted or controlled in orientation such that interlocking of the male and female components can only be made in a specified orientation. This can be advantageous in assisting proper alignment of pins, e.g., (+) to (+), and (−) to (−). The power cord connector can be keyed such that it cannot be connected in an improper orientation. In particular, the power cord connector can be a “right angle” connector, in some embodiments, yielding a low profile to decrease possible entanglements.
An Ethernet connector 168 is located on the side of housing 112 (in this example, near a back lower portion of the syringe pump 100). This location provides convenient access to other pumps, racks or communication devices that utilize Ethernet for data transfer. Ethernet connector 168 can be “ingress-protection” (or “IPX”) rated and does not require a cover. Similarly, USB port 170 is located on a side of housing 112 (in this example, near speaker 128). USB port 170 can have a cover and can be a so-called “on-the-go” connector for use with a variety of peripheral devices and applications.
Also designed to provide the stackable and user friendly design of syringe pump 100 are a set of support structures or mounting feet 172. In this example of pump 100, mounting feet 172 include two front mounting feet 172a and two rear mounting feet 172b. Front mounting feet 172a are extensions of the sides of housing 112 and rear mounting feet 172b are components that act to raise a back side of the housing 112. Rear mounting feet 172b provide clearance to the bottom portion 154 of the housing 112, such that the generally U-shaped projection 152 can extend downwardly without interfering with or causing disruption to physical stability of the pump 100. Similarly, in general, the mounting feet 172 are positioned so that stacked infusion pumps will not interfere with one another.
Also shown in
Syringe receptacle 116 contains a syringe ledge 178 on which a syringe can be operatively positioned. Syringe receptacle 116 effectively provides a cavity in the syringe pump 100 that remains open to the front of the pump 100 such that a loaded syringe is readily and substantially visible. Since the display screen 118 is located above the syringe receptacle 116, the screen 118 is generally not visually obstructed by presence of a syringe in pump 100. This non-overlapping and non-visually obscuring alignment of the receptacle and the screen simultaneously provides good visibility of both the syringe and display screen 118 in operation of pump 100.
Syringe receptacle 116 further includes an infusion line retention passage 180 (or tube guide) at one end, located opposite the end adjacent the syringe plunger driver assembly 114. The retention passage 180 provides a narrow segment in which an infusion line can pass. Specifically, retention passage 180 provides structural features which an infusion line can be looped against or around. The retention passage 180, accordingly, provides resistance from an infusion line being unintentionally pulled away from the syringe pump 100. Such pulling of the infusion line will meet resistance from the retention passage 180, rather than at the point where the infusion line is connected to a syringe located within the syringe receptacle 116.
As illustrated in, for example,
In the illustrated example of pump 100, bumper 184 of the plunger driver assembly 114 can be a generally rounded, end portion of plunger driver assembly 114 opposite the syringe receptacle 116. The bumper 184 is generally larger in diameter than the central portion of the plunger driver 182 and is made of a durable material that is relatively easy and ergonomic to grip. The bumper 184 is made for aiding in one-handed manipulation of the plunger driver assembly 114. Additionally, the “padded” construction of the bumper 184 provides some resistance to unintended impacts. Accordingly, based on its size and material, the plunger driver 182 is designed to help absorb any unintentional impacts on the plunger driver assembly 114, in an event of, for example, a dropped or mishandled syringe pump 100.
The trigger 186 is positioned at the back side of the plunger driver assembly 114. Trigger 186 is spring-loaded and acts to unlock the plunger driver assembly 114 from a locked state, such that the plunger driver assembly 114 can then relatively freely slide laterally when the trigger 186 is depressed. As depicted in, for example,
In general, the bumper 184, trigger 186, flipper 188, and barrel clamp lever 192 are used in loading and unloading operations of syringes into or out of the syringe receptacle 116. In the case of loading operations of syringes into the syringe pump 100, an initial step is to extend the plunger driver assembly 114 outwardly, away from the syringe receptacle 116. In order to accomplish this, a user can manipulate and engage the bumper 184 on the end of the plunger driver assembly 114 using the palm of his/her hand and depress the trigger 186 on the rear side of the plunger driver assembly 114 with his/her fingers of that same hand. Depressing the trigger 188 releases the plunger driver 182 from its locked position and allows the plunger driver 182 to slide outwardly and away from receptacle 116. Accordingly, the plunger driver 182 is initially slid to a desired distance appropriate for the syringe barrel of the syringe. Next, the syringe is placed into the syringe receptacle 116 such that the end of the syringe barrel abuts the interior surface of the plunger driver assembly 114 location, opposite the bumper 184. An infusion line connected to the syringe is threaded through the retention passage 180 at the end of the syringe receptacle 116 located opposite the plunger driver assembly 114. The flipper 188 rotates to descend over the thumb-press of the plunger in the syringe barrel and the barrel clamp lever 192 is manipulated so that the syringe barrel is further held in place. The user can then manipulate the user interface 110 to control the syringe pump 100 in the desired manner.
As discussed above, the user interface 110 serves as a source of data input for the syringe pump 110 from, for example, a medical practitioner or pump programmer. Although not specifically illustrated in
In this example, controller 194 is connected to the user interface and is responsible for ensuring that the pump 100 is controlled in the desired manner. Controller 194 is located in the housing 212 and controls operation of the motor 190 and drive components 196. Controller 194 may include one or more processors. Controller 194 may further include memory in some embodiments.
Motor 190 is connected to the controller 194 and syringe pump components generally. Motor 190 may be included in the plunger driver assembly 114 in some embodiments. Motor 190 is the primary means for directing the drivetrain 196 (or drive components) to effect movement of the plunger driver assembly 114. Drivetrain 196 may be a set of drive components that are at least partially located in the housing 112 which are responsible for mechanically directing infusion of fluid from a syringe that has been operatively installed in pump 100.
The syringe pump system further includes either line power via a cord connected to the power receptacle 166 or via a connector in a rack that connects to the power receptacle 166. Battery 174 provides another alternate source of power to the infusion pump 100. In an embodiment, battery 174 is fully enclosed in the housing 112 beneath the rear battery panel 164.
Various electrical components and electrical circuitry 198 are located within the housing 112 that are required for relaying or carrying out commands to the controller 194 or within the system. Various outside devices may be connected to the syringe pump 100 as well through inputs, such as an Ethernet connector 168 or USB input port 170.
The speakers 128 are equipped to provide a full range of audio output including commands, alerts, and informative communications. Plunger driver head sensors 199 and other sensors are part of the system as well. Plunger driver sensors 199 can, for example, make various measurements for tasks such as characterizing syringes, detecting occlusions, and determining plunger position. Controller 194 utilizes information gained from these sensors 199 and other components to assist in communications and decision-making in set-up and operation of pump 100.
LVP
Referring to
In general, significant portions of LVP 200 in
As seen in
The housing 212 corresponds to housing 112 and generally forms a protective shell surrounding the internal components of the LVP 200. In some embodiments, the user interface 210 may be considered part of the housing 212. The housing 212 can be characterized as generally comprising a front housing assembly 222 and a rear housing assembly 224.
Front housing assembly 222 generally surrounds the LCD display screen 218, keypad 220 and other components in the proximity of the user interface 210. Front housing assembly 222 is largely the same as the front housing assembly 122 of the syringe pump 100, however, the shape of the front housing assembly 222 around the assembly receptacle 213 and user interface 210 is shaped differently so that the features of the assembly receptacle 213 are appropriately accommodated.
Rear housing assembly 224 is generally consistent with rear housing assembly 124. Features on the rear housing assembly 224 include a handle 232, central recess 234, and a generally U-shaped retaining feature 236 defined in the top portion 230 of the housing 212. These features are analogous to those discussed with respect to the syringe pump 100 as well. The generally U-shaped upper lip portion 238 surrounding central recess 234 and receiving grooves 240 extend inwardly from rear face 242. This arrangement provides features for receiving a projection of another pump and gripping the U-shaped retaining features 236 as a handle 232.
As in the syringe pump 100, the handle 232 of the LVP 200 is integrated with housing 212 and is part of the generally U-shaped retaining feature 236. Similarly, generally U-shaped projection 252 is located on the bottom portion 254 of the housing 212 and is analogous to the generally U-shaped projection of the syringe pump 100. As in the configuration of syringe pump 100, U-shaped projection 252 is comprised of a forward portion 256 and rearward portions 258. The rearward portions 258 include a flange 260 and outwardly extending lip 262 which are sized to engage with retaining grooves 240 of another pump. Accordingly, LVPs 200 and syringe pumps 100 can be readily stacked and coupled with one another.
With particular reference to
Also shown in
The interior features of the assembly receptacle 213 are largely obstructed from view in
As depicted in, for example,
Various assemblies and methods for infusion system administration sets such as, for example, an aforementioned tubing frame assembly that can be removably secured in receptacle 213, are discussed in PCT App No. PCT/US2017/037929 of Adams et al., titled “Assemblies and Methods for Infusion Pump System Administration Sets”, and published as WO 2017/218927 A1, which is hereby incorporated by reference.
As discussed above, the user interface 210 serves as a source of data input for the syringe LVP 200 from, for example, a medical clinician or pump programmer. Although not specifically illustrated in
In this example, controller 294 is connected to the user interface and is responsible for ensuring that the pump is controlled in the desired manner. Controller 294 may include one or more processors. Controller 294 may further include memory in some embodiments.
Motor 290 is connected to the controller and LVP components generally. Motor 290 can be a stepper motor in some embodiments. In this example, motor 290 is the primary means for directing the drive components 296 to effect movement of the fingers in the assembly receptacle 213 (as illustrated in, for example,
The example of the LVP system in
Referring again to
The speakers 228 are equipped to provide a full range of audio output including commands, alerts, and informative communications. Assembly receptacle sensors 299 and other sensors can be part of the system as well. Assembly receptacle sensors 299, for example, can make various measurements for tasks such as sensing information about the particular tubing frame assembly. This can include sensing the route of infusion for which a particular tubing frame assembly is used. Sensors can be optical sensors, RFID readers, etc. Controller 294 can utilize information gained from these sensors 299 and other components to assist in communications and decision-making in set-up and operation of pump 100.
As noted above, syringe pump 100 and LVP 200 make use of a plurality of individual FRUs that enable pump components to be readily upgraded or replaced. FRU components provide ease of pump manufacture as well as simplified maintenance and replacement. Various FRU configurations contemplated herein can be interchangeable and common to both types of infusion pumps discussed. In general, FRUs can be categorized into three groups: wear components (components that will need to be replaced due to breakage or end-of-life, etc.); faster moving technology (communications, WiFi, Bluetooth®, USB, the display); and functionality upgrades (syringe security, PCA, TCI, etc.). FRUs can be interchanged between categories at times as well by virtue of these being modules with interfaces. For example, to improve the performance of a wear component, a user might upgrade the functionality. E.g., a pumping mechanism that does not meet breakage or wear component requirements could be “upgraded” by higher performance or added feature FRUs—ones that have the desired capabilities to essentially replace the previous wear component. In a pump, a higher-performance FRU can be recognized by the pump and the pump's operating parameters can be adjusted automatically to be compatible with the newly installed FRU. Additionally, the pump would have knowledge of its configuration and therefore it would essentially report back its own configuration for logging into, e.g., a DMR (Device Master Record).
In one example, both syringe pump 100 and LVP 200 have a common FRU comprising the rear portion of the pumps. This common FRU includes significant portions of the housing and rear components for both types of infusion pumps discussed. This component is shown as FRU 101 in
In some embodiments, FRUs can include components or groups of components of the pump. Examples of such FRUs can include: a rear housing assembly; an LVP front housing with motor, pump, display and keypad; a syringe front housing with display and keypad; a battery pack with gas gauge; a power supply; wireless components; a PCB BOARD assembly; a LVP door; a syringe drive; and a syringe plunger head.
In some embodiments, FRUs can include battery pack modules (additional, supplemental, or standby). Similarly, in some embodiments, FRU's can include battery charging or power modules (possibly incorporating or interfacing with portable solar, wind, or mechanical crank-type generators). Interfaces to off-the-shelf batteries for military use can be provided in some embodiments. In certain cases, a battery charging or power module can interface with one or more pumps that are “connected”. For example, a pump and a headless pump, in a stack could all interface with a battery charging or power module.
In some embodiments, FRUs can include alarm modules (both visual and/or audible). Specifically an alarm module can interface with one or more pumps that are “connected”. For example, a pump and a headless pump, in a stack could all interface with an alarm module.
In some embodiments, FRUs can include: PCA modules; syringe security devices (such as a lockbox); a communications module; or a user authentication module (such as one using biometric inputs, of fingerprints, voice, facial recognition, etc.) that can unlock an entire connected stack.
In some embodiments, FRUs of power and communication relate to alternatives to or proxies for a rack. In some embodiments, FRUs having Bluetooth® or Wifi are contemplated. In some embodiments, the FRUs can be in a daisy chain of communication (wired or wireless) and/or power. In some cases, FRUs include power selector or adapter modules. For example, modules for adaptation to local (unique) power sources or power sources that are commonly used for or in other devices (AC/DC power). In various embodiments, FRUs can be locked.
In other contemplated embodiments, the pumps themselves can be FRUs. For example, this can be the case in a collective pumping arrangement comprising a syringe pump, an LVP and a headless syringe. In some embodiments, an FRU can copy the programming of a device that has failed. See PCT App. No. PCT/US2017/042633 of Diez et al., titled “Cloning Medical Device Configurations”, and published as WO 2018/022355 A1, which is hereby incorporated by reference.
Referring to
Rack 310 permits the individual installation and removal of infusion pumps, such as syringe pumps 100. This individualized mounting capability means that a suitable syringe pump 100 or other suitable infusion pump can be readily installed or removed from a group of such pumps. This flexibility is particularly advantageous for troubleshooting and reconfiguring groups of infusion pumps.
The vertically grouped arrangement of the racked arrangement 300 in
Although
Referring to
Headless LVPs 611 may each include a generally U-shaped retaining feature 236 on their top surfaces and a generally U-shaped projection 252 on the bottom surface similar to the ones described for the LVPs 200. Accordingly the pumps can be readily coupled with so-called “tongue-and-groove” arrangement similar to the arrangements 300 and 400 in
Other ease of use features are also contemplated by this disclosure. For example, in some embodiments, all pump components with which a user is intended to interface are specially color coded. In the case of the example of syringe pump 100 herein, each of the areas for user interaction are visually color-coded blue. Accordingly, the bumper 184, trigger 186, keypad 120, barrel clamp lever 192, USB port 170, Ethernet connector 168, catch 148 and pump latch button 150 would be colored blue. In the case of the LVP 200, the latch lever 255, keypad 220, USB port 270, Ethernet connector 268, catch 248 and pump latch button 250 would be colored blue.
Throughout this disclosure and figures, generally U-shaped retaining feature 136, generally U-shaped retaining feature 236, generally U-shaped projection 152, generally U-shaped projection 252, and other features described as “generally U-shaped” should be interpreted in a largely non-limiting manner and can also be alternatively and/or interchangeably referred to understood as simply being “U-shaped”. Although the components referenced are largely understood based on their depiction from a top or bottom perspective, the “U-shaped” and “generally U-shaped” terminology should be interpreted in a largely non-limiting way. For example, the description can be understood to include one continuous largely semicircular shape or a shape having a base with two side members extending therefrom. The term “U-shape” can include base and side components having rounded or squared intersections. The side components can be disposed in parallel, converging or diverging orientations. In some embodiments, a “generally U-shaped” component is broad enough to include side members that meet at a single base location to form a “V”. Other configurations are possible as well. Accordingly, corresponding claim terms should be interpreted in a corresponding, broadly construed manner.
Various embodiments of systems, devices, and methods have been described herein. These embodiments are given only by way of example and are not intended to limit the scope of the claimed subject matter. It should be appreciated, moreover, that the various features of the embodiments that have been described may be combined in various ways to produce numerous additional embodiments. Moreover, while various materials, dimensions, shapes, configurations and locations, etc. have been described for use with disclosed embodiments, others besides those disclosed may be utilized without exceeding the scope of the claimed subject matter.
Persons of ordinary skill in the relevant arts will recognize that the subject matter hereof may comprise fewer features than illustrated in any individual embodiment described above. The embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features of the subject matter hereof may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, the various embodiments can comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art. Moreover, elements described with respect to one embodiment can be implemented in other embodiments even when not described in such embodiments unless otherwise noted.
Although a dependent claim may refer in the claims to a specific combination with one or more other claims, other embodiments can also include a combination of the dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Such combinations are proposed herein unless it is stated that a specific combination is not intended.
Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. Any incorporation by reference of documents above is further limited such that no claims included in the documents are incorporated by reference herein. Any incorporation by reference of documents above is yet further limited such that any definitions provided in the documents are not incorporated by reference herein unless expressly included herein.
For purposes of interpreting the claims, it is expressly intended that the provisions of 35 U.S.C. § 112(f) are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.
The present application claims priority to U.S. Provisional Patent Application No. 62/534,407, filed on Jul. 19, 2017, which is hereby fully incorporated herein by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/042907 | 7/19/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/018658 | 1/24/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3778195 | Bamberg | Dec 1973 | A |
4537561 | Xanthopoulos | Aug 1985 | A |
4620736 | Shanks | Nov 1986 | A |
4749109 | Kamen | Jun 1988 | A |
4756706 | Kerns | Jul 1988 | A |
4978335 | Arthur, III | Dec 1990 | A |
5034004 | Crankshaw | Jul 1991 | A |
D328952 | Arioka | Aug 1992 | S |
5236416 | McDaniel et al. | Aug 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
D344684 | Metz et al. | Mar 1994 | S |
5295966 | Stem et al. | Mar 1994 | A |
D348101 | Poli et al. | Jun 1994 | S |
5364364 | Kasvikis et al. | Nov 1994 | A |
5425173 | Moss et al. | Jun 1995 | A |
D360259 | Ijiri et al. | Jul 1995 | S |
5431509 | Anderson et al. | Jul 1995 | A |
5452807 | Foster et al. | Sep 1995 | A |
D363468 | Mieki et al. | Oct 1995 | S |
5478211 | Dominiak et al. | Dec 1995 | A |
D367527 | Marston et al. | Feb 1996 | S |
D367528 | Marston et al. | Feb 1996 | S |
D371194 | Marston et al. | Jun 1996 | S |
5533981 | Mandro et al. | Jul 1996 | A |
5545140 | Conero et al. | Aug 1996 | A |
5551850 | Williamson et al. | Sep 1996 | A |
5601420 | Warner et al. | Feb 1997 | A |
5620312 | Hyman et al. | Apr 1997 | A |
5647491 | Foster et al. | Jul 1997 | A |
5647854 | Olsen et al. | Jul 1997 | A |
D390654 | Alsberg et al. | Feb 1998 | S |
5782805 | Meinzer et al. | Jul 1998 | A |
5807322 | Lindsey et al. | Sep 1998 | A |
5814009 | Wheatman | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5823746 | Johnson | Oct 1998 | A |
5840058 | Ammann et al. | Nov 1998 | A |
5879360 | Crankshaw | Mar 1999 | A |
5901150 | Jhuboo et al. | May 1999 | A |
5904668 | Hyman et al. | May 1999 | A |
5954485 | Johnson et al. | Sep 1999 | A |
5954527 | Jhuboo et al. | Sep 1999 | A |
6019745 | Gray | Feb 2000 | A |
D435021 | Davis et al. | Dec 2000 | S |
6187400 | Woo et al. | Feb 2001 | B1 |
6195887 | Danby et al. | Mar 2001 | B1 |
6203528 | Deckert et al. | Mar 2001 | B1 |
6213723 | Danby et al. | Apr 2001 | B1 |
6213739 | Phallen et al. | Apr 2001 | B1 |
6231320 | Lawless et al. | May 2001 | B1 |
6312227 | Davis | Nov 2001 | B1 |
D455489 | Beck et al. | Apr 2002 | S |
6407335 | Franklin-Lees et al. | Jun 2002 | B1 |
6500151 | Cobb et al. | Dec 2002 | B1 |
6519569 | White et al. | Feb 2003 | B1 |
6551277 | Ford | Apr 2003 | B1 |
D474837 | Gillespie, Jr. et al. | May 2003 | S |
6575936 | Kojima et al. | Jun 2003 | B1 |
6592551 | Cobb | Jul 2003 | B1 |
6593528 | Franklin-Lees et al. | Jul 2003 | B2 |
6656148 | Das et al. | Dec 2003 | B2 |
6659976 | Beck et al. | Dec 2003 | B2 |
6722865 | Domroese | Apr 2004 | B2 |
6742992 | Davis | Jun 2004 | B2 |
6743202 | Hirschman et al. | Jun 2004 | B2 |
D501924 | Cise et al. | Feb 2005 | S |
6852094 | Beck et al. | Feb 2005 | B2 |
D504507 | Ziegler et al. | Apr 2005 | S |
D507647 | Beck et al. | Jul 2005 | S |
6966895 | Tribe | Nov 2005 | B2 |
D523553 | Beck et al. | Jun 2006 | S |
7121815 | Knuth et al. | Oct 2006 | B2 |
7160087 | Fathallah et al. | Jan 2007 | B2 |
7161488 | Frasch | Jan 2007 | B2 |
D536783 | Cise et al. | Feb 2007 | S |
7211726 | Bally et al. | May 2007 | B2 |
7214038 | Saxer et al. | May 2007 | B2 |
7227081 | Bally et al. | Jun 2007 | B2 |
7236936 | White et al. | Jun 2007 | B2 |
7273359 | Blight et al. | Sep 2007 | B2 |
7278615 | Schubert et al. | Oct 2007 | B2 |
7356382 | Vanderveen | Apr 2008 | B2 |
7422570 | Gerlach et al. | Sep 2008 | B2 |
D586463 | Evans et al. | Feb 2009 | S |
D586468 | Petersen | Feb 2009 | S |
7503808 | O'Shea | Mar 2009 | B1 |
7553291 | Duffy et al. | Jun 2009 | B2 |
7556616 | Fathallah et al. | Jul 2009 | B2 |
7632079 | Hershberger et al. | Dec 2009 | B2 |
7635349 | Tribe et al. | Dec 2009 | B2 |
D626647 | Amborn et al. | Nov 2010 | S |
7859473 | Gibson | Dec 2010 | B2 |
7884735 | Newkirk | Feb 2011 | B2 |
7896572 | Fathallah et al. | Mar 2011 | B2 |
7934912 | Voltenburg, Jr. et al. | May 2011 | B2 |
7963797 | Knappe | Jun 2011 | B2 |
7967773 | Amborn et al. | Jun 2011 | B2 |
D642677 | Boaz | Aug 2011 | S |
8062008 | Voltenburg, Jr. et al. | Nov 2011 | B2 |
8083503 | Voltenburg, Jr. et al. | Dec 2011 | B2 |
8109906 | Smisson, III et al. | Feb 2012 | B2 |
D655810 | Amborn et al. | Mar 2012 | S |
8161810 | Cadieux et al. | Apr 2012 | B2 |
8182461 | Pope et al. | May 2012 | B2 |
D669096 | Katsura | Oct 2012 | S |
8337168 | Rotem et al. | Dec 2012 | B2 |
8388582 | Eubanks et al. | Mar 2013 | B2 |
8388598 | Steinkogler | Mar 2013 | B2 |
D679379 | Katsura | Apr 2013 | S |
8430849 | Smith et al. | Apr 2013 | B2 |
8459968 | Juretich et al. | Jun 2013 | B2 |
8496613 | Zhou | Jul 2013 | B2 |
8499108 | Edwards et al. | Jul 2013 | B2 |
D691259 | Estes et al. | Oct 2013 | S |
8545458 | Gagliardoni et al. | Oct 2013 | B2 |
8551056 | Gagliardoni et al. | Oct 2013 | B2 |
8551057 | Gagliardoni et al. | Oct 2013 | B2 |
8662458 | Henault et al. | Mar 2014 | B2 |
8715224 | Kamen et al. | May 2014 | B2 |
8777590 | Moy et al. | Jul 2014 | B2 |
8834443 | Yeung | Sep 2014 | B2 |
8859972 | Cummings et al. | Oct 2014 | B2 |
8876793 | Ledford et al. | Nov 2014 | B2 |
8911403 | Flachbart et al. | Dec 2014 | B2 |
8974415 | Robert et al. | Mar 2015 | B2 |
8986252 | Cummings et al. | Mar 2015 | B2 |
9008803 | Blomquist | Apr 2015 | B2 |
9011379 | Hariharesan et al. | Apr 2015 | B2 |
D730514 | Boaz et al. | May 2015 | S |
9050411 | Kelly et al. | Jun 2015 | B2 |
9056166 | Zhu | Jun 2015 | B2 |
9072540 | Jamagin et al. | Jul 2015 | B2 |
9084848 | Schiltges et al. | Jul 2015 | B2 |
9101712 | Denis et al. | Aug 2015 | B2 |
9114213 | Murakami et al. | Aug 2015 | B2 |
9115708 | van der Merwe et al. | Aug 2015 | B2 |
9115709 | Gray et al. | Aug 2015 | B2 |
9132227 | Bryant, Jr. et al. | Sep 2015 | B2 |
9132234 | Estes et al. | Sep 2015 | B2 |
9138526 | Ware et al. | Sep 2015 | B2 |
9155825 | Kelly et al. | Oct 2015 | B2 |
9155835 | Watanabe et al. | Oct 2015 | B2 |
9162027 | Kamen et al. | Oct 2015 | B2 |
9168333 | Kelly et al. | Oct 2015 | B2 |
9183603 | Borges et al. | Nov 2015 | B2 |
9192711 | Barnes | Nov 2015 | B2 |
9192714 | Kaufmann et al. | Nov 2015 | B2 |
9205188 | Lanigan et al. | Dec 2015 | B2 |
9238101 | Hariharesan et al. | Jan 2016 | B2 |
9242035 | Karoor | Jan 2016 | B2 |
9248225 | Demers et al. | Feb 2016 | B2 |
9248230 | Geipel et al. | Feb 2016 | B2 |
9265879 | Gray | Feb 2016 | B2 |
9265890 | Chattaraj et al. | Feb 2016 | B2 |
9272089 | Jacobson et al. | Mar 2016 | B2 |
9272129 | Howlett et al. | Mar 2016 | B2 |
9278174 | Gray | Mar 2016 | B2 |
9283312 | Childers et al. | Mar 2016 | B2 |
9283370 | Travis et al. | Mar 2016 | B2 |
9289552 | Gerlach et al. | Mar 2016 | B2 |
9295778 | Kamen et al. | Mar 2016 | B2 |
9302039 | Kelly et al. | Apr 2016 | B2 |
9314566 | Wenger et al. | Apr 2016 | B2 |
9320849 | Smith et al. | Apr 2016 | B2 |
9320858 | Grimm et al. | Apr 2016 | B2 |
9339603 | Gray et al. | May 2016 | B2 |
9352083 | Heitmeiter et al. | May 2016 | B2 |
9358332 | McGill et al. | Jun 2016 | B2 |
9359885 | Slepicka et al. | Jun 2016 | B2 |
9377513 | Lindegger | Jun 2016 | B2 |
9378334 | Lee et al. | Jun 2016 | B2 |
D761741 | Santiago et al. | Jul 2016 | S |
9387286 | Kelly et al. | Jul 2016 | B2 |
9415150 | Hogard et al. | Aug 2016 | B2 |
9421313 | Kelly et al. | Aug 2016 | B2 |
9427520 | Batch et al. | Aug 2016 | B2 |
9427521 | Pope et al. | Aug 2016 | B2 |
D765832 | Hochman et al. | Sep 2016 | S |
D766204 | Takahata | Sep 2016 | S |
9446186 | Estes | Sep 2016 | B2 |
9446188 | Grant et al. | Sep 2016 | B2 |
9468713 | Hoenninger, III | Oct 2016 | B2 |
9488167 | Gray et al. | Nov 2016 | B2 |
9498573 | Smith et al. | Nov 2016 | B2 |
9526830 | Kamen et al. | Dec 2016 | B2 |
9530087 | Borges et al. | Dec 2016 | B2 |
D777119 | Lin et al. | Jan 2017 | S |
9539383 | Kohlbrecher | Jan 2017 | B2 |
9545475 | Borges et al. | Jan 2017 | B2 |
9550020 | Kelly et al. | Jan 2017 | B2 |
9554967 | Moi et al. | Jan 2017 | B2 |
9561324 | Estes | Feb 2017 | B2 |
9572919 | Kelly et al. | Feb 2017 | B2 |
9572923 | Howard et al. | Feb 2017 | B2 |
9586003 | Lee et al. | Mar 2017 | B2 |
9592338 | Pearson et al. | Mar 2017 | B2 |
9593679 | Gray et al. | Mar 2017 | B2 |
9616170 | Nakanishi et al. | Apr 2017 | B2 |
9623180 | Iio et al. | Apr 2017 | B2 |
9623198 | Kamen et al. | Apr 2017 | B2 |
D787504 | Hillman et al. | May 2017 | S |
9642965 | Marshall et al. | May 2017 | B2 |
9649431 | Gray et al. | May 2017 | B2 |
9649433 | Lanier, Jr. et al. | May 2017 | B2 |
9656052 | Slepicka et al. | May 2017 | B2 |
9662437 | Moosai | May 2017 | B2 |
9662438 | Kamen et al. | May 2017 | B2 |
9669161 | Bryant, Jr. et al. | Jun 2017 | B2 |
9682191 | Zhu | Jun 2017 | B2 |
9682199 | Walsh et al. | Jun 2017 | B2 |
9690909 | Stewart et al. | Jun 2017 | B2 |
D791937 | Schoenig et al. | Jul 2017 | S |
9707336 | Dang et al. | Jul 2017 | B2 |
D793346 | Folk et al. | Aug 2017 | S |
9724456 | Muller et al. | Aug 2017 | B2 |
9724458 | Grant et al. | Aug 2017 | B2 |
9731072 | Estes | Aug 2017 | B2 |
9744304 | Swift et al. | Aug 2017 | B2 |
9753015 | Bardina et al. | Sep 2017 | B2 |
D800717 | Hillman et al. | Oct 2017 | S |
D801519 | Sabin et al. | Oct 2017 | S |
9775964 | Eubanks et al. | Oct 2017 | B2 |
9789247 | Kamen et al. | Oct 2017 | B2 |
9789251 | Robert et al. | Oct 2017 | B2 |
9795729 | Childers et al. | Oct 2017 | B2 |
D803386 | Sabin et al. | Nov 2017 | S |
D803387 | Bodwell et al. | Nov 2017 | S |
9808316 | Hasegawa | Nov 2017 | B2 |
9821151 | Juretich et al. | Nov 2017 | B2 |
9839743 | Lanigan et al. | Dec 2017 | B2 |
9839745 | Paul et al. | Dec 2017 | B2 |
9839775 | McGill et al. | Dec 2017 | B2 |
9839776 | Helmore et al. | Dec 2017 | B2 |
9849235 | Mandro et al. | Dec 2017 | B2 |
9861732 | Scarpaci et al. | Jan 2018 | B2 |
9861740 | Adams | Jan 2018 | B2 |
9872950 | Kelly et al. | Jan 2018 | B2 |
D810958 | Lacy et al. | Feb 2018 | S |
9886550 | Lee et al. | Feb 2018 | B2 |
9895488 | Morton | Feb 2018 | B2 |
D812218 | Lacy et al. | Mar 2018 | S |
9907943 | Grant et al. | Mar 2018 | B2 |
9925315 | Eubanks et al. | Mar 2018 | B2 |
9931461 | Kamen et al. | Apr 2018 | B2 |
9932977 | Bresina et al. | Apr 2018 | B2 |
9943653 | Kamen et al. | Apr 2018 | B2 |
9968739 | Zollinger et al. | May 2018 | B2 |
9976551 | Blomquist | May 2018 | B2 |
9987410 | Helmore et al. | Jun 2018 | B2 |
9993600 | Lanier, Jr. et al. | Jun 2018 | B2 |
10004847 | Wander et al. | Jun 2018 | B2 |
D823456 | Lacy et al. | Jul 2018 | S |
10022494 | Shimizu | Jul 2018 | B2 |
D828547 | Lacy et al. | Sep 2018 | S |
10076608 | Dowden et al. | Sep 2018 | B2 |
D830546 | Lacy et al. | Oct 2018 | S |
D840021 | Lacy et al. | Feb 2019 | S |
D846735 | Sanborn et al. | Apr 2019 | S |
D870263 | Adams et al. | Dec 2019 | S |
D871572 | Lacy et al. | Dec 2019 | S |
20010013437 | Husted | Aug 2001 | A1 |
20010044602 | Angersbach et al. | Nov 2001 | A1 |
20020107476 | Mann et al. | Aug 2002 | A1 |
20020134570 | Franklin-Lees et al. | Sep 2002 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030161744 | Vilks et al. | Aug 2003 | A1 |
20030214412 | Ho et al. | Nov 2003 | A1 |
20040057855 | Gerlach et al. | Mar 2004 | A1 |
20040167464 | Ireland et al. | Aug 2004 | A1 |
20040220526 | Boyne-Aitken | Nov 2004 | A1 |
20060129110 | Smith et al. | Jun 2006 | A1 |
20060184121 | Brockman et al. | Aug 2006 | A1 |
20060229577 | Roe et al. | Oct 2006 | A1 |
20070073236 | Mernoe et al. | Mar 2007 | A1 |
20070074596 | Siefert | Apr 2007 | A1 |
20070088249 | Duffy et al. | Apr 2007 | A1 |
20070167912 | Causey et al. | Jul 2007 | A1 |
20070179444 | Causey et al. | Aug 2007 | A1 |
20080103375 | Kiani | May 2008 | A1 |
20080200870 | Palmroos et al. | Aug 2008 | A1 |
20080281168 | Gibson et al. | Nov 2008 | A1 |
20080294142 | Patel et al. | Nov 2008 | A1 |
20080306437 | Jacobson | Dec 2008 | A1 |
20090043252 | Haylor et al. | Feb 2009 | A1 |
20090069749 | Miller et al. | Mar 2009 | A1 |
20090153058 | Feng et al. | Jun 2009 | A1 |
20090153463 | Arrizza et al. | Jun 2009 | A1 |
20090153595 | Cozmi et al. | Jun 2009 | A1 |
20090157432 | Palmroos et al. | Jun 2009 | A1 |
20090171289 | Davis et al. | Jul 2009 | A1 |
20090177180 | Rubalcaba, Jr. et al. | Jul 2009 | A1 |
20090177991 | Davis et al. | Jul 2009 | A1 |
20090177992 | Rubalcaba, Jr. et al. | Jul 2009 | A1 |
20090183105 | Teel, IV et al. | Jul 2009 | A1 |
20090183147 | Davis et al. | Jul 2009 | A1 |
20090247982 | Krulevitch et al. | Oct 2009 | A1 |
20100010647 | Schroeder et al. | Jan 2010 | A1 |
20100100037 | Cozmi et al. | Apr 2010 | A1 |
20110040247 | Mandro et al. | Feb 2011 | A1 |
20110097229 | Cauley III et al. | Apr 2011 | A1 |
20110106004 | Eubanks et al. | May 2011 | A1 |
20110106318 | Ledford | May 2011 | A1 |
20110184383 | Hasegawa | Jul 2011 | A1 |
20110300010 | Jamagin et al. | Dec 2011 | A1 |
20110313358 | Hariharesan et al. | Dec 2011 | A1 |
20120004624 | Brown et al. | Jan 2012 | A1 |
20120023808 | Lagunas-Solar et al. | Feb 2012 | A1 |
20120083760 | Ledford | Apr 2012 | A1 |
20120101437 | Gagliardoni et al. | Apr 2012 | A1 |
20120130308 | Silkaitis et al. | May 2012 | A1 |
20120130309 | Hariharesan et al. | May 2012 | A1 |
20120266964 | West et al. | Oct 2012 | A1 |
20120266965 | Hariharesan et al. | Oct 2012 | A1 |
20130053820 | Estes et al. | Feb 2013 | A1 |
20130115120 | Jamagin et al. | May 2013 | A1 |
20130131585 | Eubanks et al. | May 2013 | A1 |
20130267899 | Robert et al. | Oct 2013 | A1 |
20130272773 | Kamen et al. | Oct 2013 | A1 |
20130281965 | Kamen et al. | Oct 2013 | A1 |
20140100526 | Ueda et al. | Apr 2014 | A1 |
20140188076 | Kamen et al. | Jul 2014 | A1 |
20140200510 | Agard et al. | Jul 2014 | A1 |
20140249500 | Estes | Sep 2014 | A1 |
20140259837 | Belliveau | Sep 2014 | A1 |
20140271246 | Zollinger et al. | Sep 2014 | A1 |
20140271247 | Abal | Sep 2014 | A1 |
20140276424 | Davis et al. | Sep 2014 | A1 |
20140317929 | Robert et al. | Oct 2014 | A1 |
20140358111 | Brewer et al. | Dec 2014 | A1 |
20150018766 | Nakanishi et al. | Jan 2015 | A1 |
20150023808 | Zhu | Jan 2015 | A1 |
20150041419 | Hawegawa | Feb 2015 | A1 |
20150133890 | Wander et al. | May 2015 | A1 |
20150157791 | Desch et al. | Jun 2015 | A1 |
20150265768 | Vazquez et al. | Sep 2015 | A1 |
20150273140 | Bresina et al. | Oct 2015 | A1 |
20150275887 | Koyama et al. | Oct 2015 | A1 |
20150297832 | Blomquist | Oct 2015 | A1 |
20150314066 | Shimizu | Nov 2015 | A1 |
20160058939 | Brewer et al. | Mar 2016 | A1 |
20160084434 | Janway et al. | Mar 2016 | A1 |
20160228633 | Welsch et al. | Aug 2016 | A1 |
20160235910 | Damiano et al. | Aug 2016 | A1 |
20160250410 | Traversaz et al. | Sep 2016 | A1 |
20170028126 | Moosai | Feb 2017 | A1 |
20170100536 | Estes | Apr 2017 | A1 |
20170182244 | Blomquist | Jun 2017 | A1 |
20170189605 | Blomquist | Jul 2017 | A1 |
20170203032 | Dowden et al. | Jul 2017 | A1 |
20170213012 | O'Scolai et al. | Jul 2017 | A1 |
20170258985 | Adams et al. | Sep 2017 | A1 |
20170277851 | Adams et al. | Sep 2017 | A1 |
20170281864 | Searle et al. | Oct 2017 | A1 |
20180117241 | Amborn et al. | May 2018 | A1 |
20180140770 | Hetchler et al. | May 2018 | A1 |
20180202429 | Bresina et al. | Jul 2018 | A1 |
20180353678 | Adams et al. | Dec 2018 | A1 |
20200179592 | Adams et al. | Jun 2020 | A1 |
Number | Date | Country |
---|---|---|
2009348770 | Apr 2015 | AU |
2010208446 | Sep 2015 | AU |
2011293619 | Sep 2015 | AU |
2010286957 | Oct 2015 | AU |
2009348755 | Nov 2015 | AU |
2010208447 | Nov 2015 | AU |
2010273694 | Dec 2015 | AU |
2011280208 | Dec 2015 | AU |
2012258687 | Feb 2016 | AU |
2013260724 | Apr 2016 | AU |
2015328081 | Jul 2016 | AU |
2015330980 | Jul 2016 | AU |
2012340056 | Nov 2016 | AU |
2014277760 | Feb 2017 | AU |
2016200525 | Feb 2017 | AU |
2012387311 | Jul 2017 | AU |
2015209670 | Jul 2017 | AU |
2014207809 | Aug 2017 | AU |
2013230954 | Sep 2017 | AU |
2015209669 | Oct 2017 | AU |
2014234996 | Dec 2017 | AU |
201810386 | Feb 2018 | AU |
2012258687 | Mar 2018 | AU |
2013361569 | May 2018 | AU |
2014225658 | May 2018 | AU |
2018302257 | Jan 2020 | AU |
2018388965 | Jul 2020 | AU |
2019263493 | Nov 2020 | AU |
2812551 | Jun 2015 | CA |
2711244 | Feb 2016 | CA |
2751513 | Apr 2016 | CA |
2765880 | Apr 2016 | CA |
2712930 | Jul 2016 | CA |
2704411 | Sep 2016 | CA |
2765967 | Oct 2016 | CA |
2765968 | Oct 2016 | CA |
2928503 | Oct 2016 | CA |
2928505 | Nov 2016 | CA |
2709193 | Jan 2017 | CA |
2812555 | Feb 2017 | CA |
2713028 | Apr 2017 | CA |
2712945 | Jun 2017 | CA |
2749557 | Jun 2017 | CA |
2750335 | Jun 2017 | CA |
2702385 | Jul 2017 | CA |
2712947 | Jul 2017 | CA |
2720492 | Jul 2017 | CA |
2866022 | Aug 2017 | CA |
2712950 | Oct 2017 | CA |
2560996 | Nov 2017 | CA |
2772599 | Nov 2017 | CA |
2805738 | Nov 2017 | CA |
3027961 | Dec 2017 | CA |
2768205 | Jan 2018 | CA |
2780286 | Jan 2018 | CA |
2767986 | Apr 2018 | CA |
3069538 | Jan 2019 | CA |
3086175 | Jun 2019 | CA |
179406 | Sep 2019 | CA |
3099115 | Nov 2019 | CA |
101990446 | Mar 2011 | CN |
102065931 | May 2011 | CN |
102292117 | Dec 2011 | CN |
102481447 | May 2012 | CN |
104334209 | Feb 2015 | CN |
104640584 | May 2015 | CN |
201730157329.3 | Jul 2018 | CN |
201830031970.7 | Nov 2018 | CN |
109414545 | Mar 2019 | CN |
110944697 | Mar 2020 | CN |
111683701 | Sep 2020 | CN |
112074313 | Dec 2020 | CN |
4030368 | Nov 1991 | DE |
10348653 | May 2005 | DE |
003933993-0001 | May 2017 | EM |
003933993-0002 | May 2017 | EM |
003933993-0003 | May 2017 | EM |
003933993-0004 | May 2017 | EM |
003933993-0005 | May 2017 | EM |
003934447-0001 | May 2017 | EM |
003934447-0002 | May 2017 | EM |
003934447-0003 | May 2017 | EM |
003934447-0004 | May 2017 | EM |
4680353-0001 | Jan 2018 | EM |
4680353-0002 | Jan 2018 | EM |
4680353-0003 | Jan 2018 | EM |
0477551 | Apr 1992 | EP |
0780134 | Jun 1997 | EP |
0655107 | Oct 2002 | EP |
0999860 | Jan 2004 | EP |
0839062 | Sep 2004 | EP |
1186311 | Nov 2004 | EP |
1616588 | Mar 2006 | EP |
1664536 | Oct 2007 | EP |
1787024 | Nov 2009 | EP |
1768723 | Aug 2010 | EP |
2077874 | Sep 2011 | EP |
1557187 | Apr 2012 | EP |
2445573 | Jan 2014 | EP |
2542781 | Mar 2014 | EP |
2398533 | Apr 2014 | EP |
2298388 | Jul 2015 | EP |
2298389 | Aug 2015 | EP |
2924289 | Sep 2015 | EP |
2596819 | Nov 2015 | EP |
2319551 | Jan 2016 | EP |
1381889 | Mar 2016 | EP |
2254615 | Mar 2016 | EP |
2298378 | Mar 2016 | EP |
2252346 | Apr 2016 | EP |
2519288 | Apr 2016 | EP |
2173433 | May 2016 | EP |
2736551 | May 2016 | EP |
2252347 | Jul 2016 | EP |
2254616 | Jul 2016 | EP |
2570826 | Aug 2016 | EP |
2173402 | Sep 2016 | EP |
2252345 | Sep 2016 | EP |
2453950 | Oct 2016 | EP |
2621452 | Nov 2016 | EP |
2606922 | Feb 2017 | EP |
2197513 | Apr 2017 | EP |
2295091 | Apr 2017 | EP |
2604301 | May 2017 | EP |
2883559 | Jun 2017 | EP |
2902048 | Jun 2017 | EP |
2381978 | Jul 2017 | EP |
2896417 | Jul 2017 | EP |
1680176 | Aug 2017 | EP |
2736564 | Aug 2017 | EP |
1881786 | Nov 2017 | EP |
2183016 | Nov 2017 | EP |
3037117 | Dec 2017 | EP |
2700424 | Jan 2018 | EP |
2260891 | Mar 2018 | EP |
2968741 | May 2018 | EP |
3085402 | May 2018 | EP |
3471796 | Apr 2019 | EP |
3655065 | May 2020 | EP |
3727497 | Oct 2020 | EP |
2302140 | Apr 1998 | GB |
2338992 | Sep 2000 | GB |
61475 | Jan 2018 | IL |
60330 | Apr 2018 | IL |
61476 | Apr 2018 | IL |
61546 | Nov 2018 | IL |
3267404 | Mar 2002 | JP |
3290263 | Jun 2002 | JP |
3382622 | Mar 2003 | JP |
3885018 | Feb 2007 | JP |
3931013 | Jun 2007 | JP |
4394072 | Jan 2010 | JP |
4507233 | Jul 2010 | JP |
4674689 | Apr 2011 | JP |
4805724 | Nov 2011 | JP |
4833732 | Dec 2011 | JP |
4939707 | May 2012 | JP |
2012107555 | Jun 2012 | JP |
2012516208 | Jul 2012 | JP |
5180479 | Apr 2013 | JP |
5235042 | Jul 2013 | JP |
2013153864 | Aug 2013 | JP |
5308575 | Oct 2013 | JP |
5457365 | Apr 2014 | JP |
5543493 | Jul 2014 | JP |
5595930 | Sep 2014 | JP |
5619029 | Nov 2014 | JP |
5720193 | May 2015 | JP |
2015181554 | Oct 2015 | JP |
2016508045 | Mar 2016 | JP |
3378054 | Feb 2017 | JP |
1588670 | Sep 2017 | JP |
1588671 | Sep 2017 | JP |
1591102 | Oct 2017 | JP |
1619335 | Nov 2018 | JP |
2019525784 | Sep 2019 | JP |
2020527417 | Sep 2020 | JP |
423975 | Apr 2018 | NZ |
WO 2001036027 | May 2001 | WO |
WO 2004037322 | May 2004 | WO |
WO 2005037349 | Apr 2005 | WO |
WO 2010023915 | Mar 2010 | WO |
WO 2010088143 | Aug 2010 | WO |
WO 2010088144 | Aug 2010 | WO |
WO 2010149187 | Dec 2010 | WO |
WO 2011008619 | Jan 2011 | WO |
WO 2011008621 | Jan 2011 | WO |
WO 2011008624 | Jan 2011 | WO |
WO 2011025588 | Mar 2011 | WO |
WO 2011025589 | Mar 2011 | WO |
WO 2012009697 | Jan 2012 | WO |
WO 2012039300 | Mar 2012 | WO |
WO 2014089008 | Jun 2014 | WO |
WO 2014100744 | Jun 2014 | WO |
WO 2014159466 | Oct 2014 | WO |
WO 2016014335 | Jan 2016 | WO |
WO 2016018552 | Feb 2016 | WO |
WO 2016179389 | Nov 2016 | WO |
WO 2016183342 | Nov 2016 | WO |
WO 2016196098 | Dec 2016 | WO |
WO 2017218927 | Dec 2017 | WO |
WO 2018022355 | Feb 2018 | WO |
WO 2019018658 | Jan 2019 | WO |
WO 2019055516 | Mar 2019 | WO |
WO 2019125941 | Jun 2019 | WO |
WO 2019213496 | Nov 2019 | WO |
Entry |
---|
US 9,222,472 B2, 12/2015, Gray et al. (withdrawn) |
US 9,320,848 B2, 04/2016, Grant et al. (withdrawn) |
US 9,867,954 B2, 01/2018, Grant et al. (withdrawn) |
DE 4030368C1 translation (Year: 1991). |
memteknoloji.com, Stackable Syringe Pump Dixson Instilar 1438, undated online product page, retrieved Sep. 18, 2018 from <URL:http://memteknoloji.com/dixion/www.dixion.de/en/catalogue/intensi-vstation-4/injektionspumpen-4/stapelbare-injektionspumpe-instilar-1438-3.h-tml> (Year: 2018). |
Emsworld.com, Space Infusion Pump System, undated online product page, retrieved Sep. 18, 2018 from <URL:https://www.emsworld.com/product/10264356/space-infusion-pump-sys-tem> (Year: 2018). |
FMH Employees, “Pediatric Pump Operation: Medfusion Syringe Pump,” Mar. 28, 2012, Retrieved from the Internet (Jun. 27, 2019). |
PCT Application No. PCT/US2018/042907, Search Report and Written Opinion dated Jan. 15, 2020, 15 pages. |
Application and File History for U.S. Appl. No. 15/733,222, filed Jun. 11, 2020. Inventors: Adams et al. |
Application and File History for U.S. Appl. No. 16/309,909, filed Dec. 13, 2018. Inventors: Adams et al. |
Application and File History for U.S. Appl. No. 17/250,010, filed Oct. 30, 2020. Inventors: Peterson et al. |
Application and File History for U.S. Appl. No. 29/583,354, filed Nov. 4, 2016. Inventors: Lacy et al. |
Application and File History for U.S. Appl. No. 29/583,359, filed Sep. 11, 2018. Inventors: Lacy et al. |
Application and File History for U.S. Appl. No. 29/583,361, filed Feb. 20, 2018. Inventors: Lacy et al. |
Application and File History for U.S. Appl. No. 29/586,520, filed Jul. 17, 2018, Inventors: Lacy et al. |
Number | Date | Country | |
---|---|---|---|
20200129691 A1 | Apr 2020 | US |
Number | Date | Country | |
---|---|---|---|
62534407 | Jul 2017 | US |